FDA Calls For More Review Of Aortic Valve Reduced Leaflet Motion
This article was originally published in The Gray Sheet
The agency issued a notification that recent advanced imaging studies have shown reduced leaflet motion in bioprosthetic aortic valves. While FDA believes the devices are reasonably safe and effective, it is working with cardiology societies to design new clinical studies to explore the phenomenon.
You may also be interested in...
The worldwide voluntary removal comes in response to reports that the pin that connects the valve to the delivery system sometimes releases prematurely, most likely due to excess tension created during manufacturing.
South Korea has formulated new detailed policy measures to support the formation of major bioclusters, which will offer tax and other incentives in a bid to lure foreign firms and talent.
Abrysvo is recommended for use in pregnant people 32-36 weeks gestation if administered from September to January. For infants whose mothers were not vaccinated in this window, nirsevimab is recommended for prevention of respiratory syncytial virus infection.